LIVE
ABBV
AbbVie Inc. · Pharmaceuticals
$223.07
+10.68% this month
VERSUS
⟷
COMPARE
JNJ
Johnson & Johnson · Healthcare (Pharma & MedTech)
$232.16
+4.90% this month
AI Score
53.3vs43.5
ABBV ↑1Y Return
+17.51%vs+49.75%
JNJ ↑Forward P/E
13.99xvs18.30x
ABBV ↑Target Upside
+11.58%vs+8.63%
ABBV ↑Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
ABBV
4
JNJ
1
Metrics last refreshed: 6/9/2026
Quick take
ABBV vs JNJ: AbbVie vs Johnson & Johnson Stock Comparison: AI Score, Valuation, Performance and Upside
AbbVie is a focused pharmaceutical company executing on a clear post-Humira transition with Skyrizi and Rinvoq, plus the Allergan aesthetics franchise; Johnson & Johnson is a diversified healthcare company spanning innovative pharmaceuticals and a large MedTech business. AbbVie offers a higher dividend yield and a clearer near-term growth narrative; JNJ offers more business diversification and MedTech exposure.
Use this ABBV vs JNJ comparison to choose between a high-yield focused pharma compounder and a diversified healthcare quality franchise. AbbVie's Skyrizi/Rinvoq transition is the clearest near-term driver; JNJ's value lies in the combination of its pharma pipeline and MedTech robotic surgery growth.
Live analysis · updated 6/9/2026
ABBV holds the edge across 4 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+49.75% vs +17.51%), though ABBV trades at the lower forward P/E (13.99x vs 18.30x). ABBV leads on both revenue growth (12.40%) and operating margin (32.16%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +11.58% for ABBV and +8.63% for JNJ.
Comparison scoreboard
ABBV LEADS 4/5AI Score
ABBV ✓53.3
JNJ 43.5
1Y Return
ABBV +17.51%
JNJ ✓+49.75%
Fwd P/E
ABBV ✓13.99
JNJ 18.30
Target Up.
ABBV ✓+11.58%
JNJ +8.63%
Op. Margin
ABBV ✓32.16%
JNJ 27.41%
Normalized 1Y performance
ABBV
JNJ
Recent returns
ABBV
JNJ
Analyst price targets & sentiment
ABBV · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$170.00
analyst mean$253.55
current price$223.07
+11.6% upside to analyst mean
JNJ · 23 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.3/5.0)
Price target range
analyst low$150.00
analyst mean$252.87
current price$232.16
+8.6% upside to analyst mean
Who should consider this stock?
ABBV may suit investors who:
- →Want a high-dividend-yield pharmaceutical compounder with a clear post-Humira growth transition
- →Value Skyrizi and Rinvoq as proven blockbusters continuing to grow faster than Humira declines
- →Like the Botox/Allergan franchise as a durable aesthetics and therapeutics revenue stream
- →Prefer a more focused pharmaceutical holding without the MedTech complexity of JNJ
JNJ may suit investors who:
- →Want diversified healthcare exposure spanning both innovative pharmaceuticals and MedTech devices
- →Value Darzalex's oncology growth and Ottava robotic surgery as distinct long-term catalysts
- →Prefer a lower-yield but more durable Dividend King with 60+ consecutive years of dividend growth
- →Seek a more defensive healthcare holding with two business segments that partially offset each other cyclically
Performance & AI score
| Metric | ABBV | JNJ |
|---|---|---|
| AI score | 53.3 | 43.5 |
| AI rank | #319 | #794 |
| Latest close | $223.07 | $232.16 |
| 1M return | +10.68% | +4.90% |
| 6M return | -1.33% | +14.97% |
| 1Y return | +17.51% | +49.75% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | JNJ |
|---|---|---|
| 1Y ago | $11.79K (+17.9%) started 2025-06-09 | $14.96K (+49.6%) started 2025-06-09 |
| 5Y ago | $27.04K (+170.4%) started 2021-06-09 | $17.48K (+74.8%) started 2021-06-09 |
| 10Y ago | $85.02K (+750.2%) started 2016-06-09 | $33.08K (+230.8%) started 2016-06-09 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | ABBV | JNJ |
|---|---|---|
| Market cap | $401.47B | $560.33B |
| Trailing P/E | 110.84 | 26.94 |
| Forward P/E | 13.99 | 18.30 |
| Price/Sales | 5.85 | 4.18 |
| EV/Revenue | 7.40 | 6.16 |
| Analyst target | $253.55 | $252.87 |
| Target upside | +11.58% | +8.63% |
Growth, profitability & risk
| Metric | ABBV | JNJ |
|---|---|---|
| Revenue growth | 12.40% | 9.90% |
| Earnings growth | -46.20% | -52.90% |
| EPS growth | -46.20% | -52.90% |
| FCF margin | +33.13% | +12.98% |
| Operating margin | 32.16% | 27.41% |
| Profit margin | 5.79% | 21.83% |
| ROIC proxy | 6225.00% | 26.42% |
| Return on equity | 6225.00% | 26.42% |
| Dividend yield | 3.05% | 2.30% |
| Beta | 0.31 | 0.26 |
| Debt/equity | 4789.60 | 67.73 |
| Current ratio | 0.80 | 1.02 |
| Quick ratio | 0.52 | 0.69 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
ABBV max drawdown19.23%
JNJ max drawdown10.96%
ABBV max wkly drop8.49%
JNJ max wkly drop5.81%
5Y risk snapshot
ABBV max drawdown21.92%
JNJ max drawdown18.41%
ABBV max wkly drop17.30%
JNJ max wkly drop9.18%
10Y risk snapshot
ABBV max drawdown45.09%
JNJ max drawdown27.37%
ABBV max wkly drop19.39%
JNJ max wkly drop13.25%
Performance metrics by period
| Period | Metric | ABBV | JNJ |
|---|---|---|---|
| 1Y | Growth | +17.93% | +49.56% |
| CAGR | +18.01% | +49.81% | |
| Sharpe ratio | 0.62 | 2.22 | |
| Max drawdown | 19.23% | 10.96% | |
| Max daily drop | 5.20% | 2.37% | |
| Max wkly drop | 8.49% | 5.81% | |
| 5Y | Growth | +128.58% | +56.10% |
| CAGR | +17.99% | +9.32% | |
| Sharpe ratio | 0.64 | 0.35 | |
| Max drawdown | 21.92% | 18.41% | |
| Max daily drop | 12.57% | 7.59% | |
| Max wkly drop | 17.30% | 9.18% | |
| 10Y | Growth | +436.96% | +152.36% |
| CAGR | +18.31% | +9.70% | |
| Sharpe ratio | 0.61 | 0.35 | |
| Max drawdown | 45.09% | 27.37% | |
| Max daily drop | 16.25% | 10.04% | |
| Max wkly drop | 19.39% | 13.25% |
Business comparison
| Category | ABBV | JNJ |
|---|---|---|
| Company | AbbVie Inc. | Johnson & Johnson |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Large-cap pharmaceutical company. Core immunology drugs include Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are replacing Humira as the revenue drivers. Also markets Botox (aesthetics and therapeutics), Vraylar (psychiatry), and Venclexta (oncology) through the Allergan acquisition. | Diversified healthcare company split into Innovative Medicine (pharmaceuticals) and MedTech (surgical robotics, orthopedics, cardiovascular, vision). Kenvue (consumer health) was spun off in 2023. Core drugs include Darzalex, Tremfya, Erleada, and Carvykti. |
| Investor focus | Skyrizi and Rinvoq revenue trajectory replacing Humira erosion, Allergan aesthetics recovery, psychiatry pipeline, and dividend sustainability. | Innovative Medicine pipeline productivity, MedTech robotic surgery growth, Darzalex and Tremfya as post-Stelara growth anchors, talc litigation resolution, and dividend growth. |
ABBV strengths
- →Skyrizi and Rinvoq are both growing rapidly and are expected to generate more combined revenue than Humira at peak
- →Allergan acquisition adds Botox franchise — a durable, aesthetics-and-neurology revenue stream
- →One of the highest dividend yields in large-cap pharmaceuticals, with a track record of consistent growth
JNJ strengths
- →Two distinct high-quality businesses in one holding — Innovative Medicine and MedTech both operate at scale
- →Darzalex (multiple myeloma) is one of the fastest-growing large-cap pharma drugs and has multiple new indication opportunities
- →MedTech Ottava robotic surgery system represents a significant new growth platform if commercially validated
Risks to watch — ABBV
- →Humira biosimilar erosion is ongoing — revenue from the world's former best-selling drug continues to decline
- →Skyrizi and Rinvoq must sustain strong growth to fully offset Humira losses — execution is critical
- →High debt from the Allergan acquisition, though being progressively paid down from strong cash flows
Risks to watch — JNJ
- →Talc litigation overhang — ongoing legal proceedings related to baby powder asbestos claims create headline risk
- →Stelara (psoriasis/IBD) facing biosimilar competition — this blockbuster drug is in revenue decline
- →MedTech competitive dynamics in robotic surgery (Intuitive Surgical's dominant position is hard to dislodge)
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
All stock comparisons
AAPL vs MSFTApple Inc. vs Microsoft Corporation
CEG vs VSTConstellation Energy Corporation vs Vistra Corp.
CRWD vs PANWCrowdStrike Holdings vs Palo Alto Networks
IONQ vs QBTSIonQ vs D-Wave Quantum Inc.
LITE vs COHRLumentum Holdings Inc. vs Coherent Corp.
NVDA vs AMDNVIDIA Corporation vs Advanced Micro Devices
MU vs AMDMicron Technology vs Advanced Micro Devices
COST vs WMTCostco Wholesale Corporation vs Walmart Inc.
TSLA vs RIVNTesla vs Rivian Automotive
NVDA vs INTCNVIDIA Corporation vs Intel Corporation
MSFT vs GOOGLMicrosoft Corporation vs Alphabet Inc.
META vs SNAPMeta Platforms vs Snap Inc.
NFLX vs DISNetflix vs The Walt Disney Company
UBER vs LYFTUber Technologies vs Lyft
JPM vs GSJPMorgan Chase & Co. vs The Goldman Sachs Group
V vs MAVisa Inc. vs Mastercard Incorporated
AMZN vs GOOGLAmazon.com vs Alphabet Inc.
XOM vs CVXExxon Mobil Corporation vs Chevron Corporation
SQ vs PYPLBlock vs PayPal Holdings
ABNB vs BKNGAirbnb vs Booking Holdings
NVO vs LLYNovo Nordisk A/S vs Eli Lilly and Company
NET vs ZSCloudflare vs Zscaler
APP vs TTDAppLovin Corporation vs The Trade Desk
SMCI vs DELLSuper Micro Computer vs Dell Technologies Inc.
RBLX vs URoblox Corporation vs Unity Software Inc.
MELI vs SEMercadoLibre vs Sea Limited
ARM vs QCOMArm Holdings plc vs Qualcomm Incorporated
SPOT vs AAPLSpotify Technology S.A. vs Apple Inc.
DKNG vs MGMDraftKings Inc. vs MGM Resorts International
PLTR vs AIPalantir Technologies Inc. vs C3.ai
JPM vs BACJPMorgan Chase & Co. vs Bank of America Corporation
KO vs PEPThe Coca-Cola Company vs PepsiCo
F vs GMFord Motor Company vs General Motors Company
META vs GOOGLMeta Platforms vs Alphabet Inc.
WMT vs AMZNWalmart Inc. vs Amazon.com
ADBE vs CRMAdobe Inc. vs Salesforce
AMD vs INTCAdvanced Micro Devices vs Intel Corporation
PFE vs MRNAPfizer Inc. vs Moderna
BA vs LMTThe Boeing Company vs Lockheed Martin Corporation
SBUX vs MCDStarbucks Corporation vs McDonald's Corporation
HD vs LOWThe Home Depot vs Lowe's Companies
TSLA vs FTesla vs Ford Motor Company
AMZN vs MSFTAmazon.com vs Microsoft Corporation
SNOW vs PLTRSnowflake Inc. vs Palantir Technologies Inc.
RIVN vs LCIDRivian Automotive vs Lucid Group
COIN vs HOODCoinbase Global vs Robinhood Markets
CRM vs NOWSalesforce vs ServiceNow
CAT vs DECaterpillar Inc. vs Deere & Company
BAC vs WFCBank of America Corporation vs Wells Fargo & Company
SHOP vs AMZNShopify Inc. vs Amazon.com
TSM vs NVDATaiwan Semiconductor Manufacturing Company vs NVIDIA Corporation
BX vs KKRBlackstone Inc. vs KKR & Co. Inc.
MARA vs RIOTMARA Holdings vs Riot Platforms
AMGN vs LLYAmgen Inc. vs Eli Lilly and Company
OXY vs CVXOccidental Petroleum Corporation vs Chevron Corporation
DIS vs WBDThe Walt Disney Company vs Warner Bros. Discovery
PYPL vs VPayPal Holdings vs Visa Inc.
GOOGL vs AAPLAlphabet Inc. (Google) vs Apple Inc.
ANET vs CSCOArista Networks vs Cisco Systems